This was the stock's second consecutive day of losses.

Shares of Catalyst Pharmaceuticals Inc. CPRX shed 1.43% to $24.11 Thursday, on what proved to be an all-around grim trading ...

Renaissance Investment Management, an investment management company, released its Q4 2024 “Small Cap Growth Strategy” investor letter. A copy of the letter can be downloaded here. The Russell 2000 ...

Catalyst Pharmaceuticals Stock Performance Catalyst Pharmaceuticals stock opened at $24.46 on Thursday. The firm has a market cap of $2.97 billion, a price-to-earnings ratio of 20.73, a price-to ...

As predicted by many analysts, economists, and investors, the sweeping tariffs announced by the Trump administration on Wednesday decimated the stock market on Thursday. It had one of its worst ...

In its fourth quarter 2024 investor letter, Renaissance Investment Management Small Cap Growth Strategy emphasized stocks such as Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX). Catalyst ...

Supernus Pharmaceuticals got a positive adjustment to its Relative Strength (RS) Rating, from 67 to 81. Please watch the ...

BioMarin Pharmaceutical Inc.’s BMRN share price has dipped by 10.70%, which has investors questioning if this is right time ...

Zenas BioPharma, Inc.'s obexelimab's potential in treating autoimmune diseases and upcoming phase 2 & 3 trial results. Read ...

Larimar stock is down over 50% this year due to anaphylactic reactions in a study, rising expenses, and cautious market ...